Oxford COVID-19 vaccine prompts immune response among young, elderly adults

Advertisements

A COVID-19 vaccine being developed by Oxford University that is considered a frontrunner in the race for an inoculation against the deadly bug produces a similar immune response among older and younger adults, UK drug maker AstraZeneca said Monday.
The vaccine’s adverse reactions also were lower among the elderly, the company said, according to Reuters.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told the news outlet.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the rep added, using the scientific name of the vaccine.
News that older adults get an immune response is encouraging because the immune system weakens with age and older people are those who are most at risk of dying from the disease.
The Financial Times has reported that the vaccine — being developed by Oxford and AstraZeneca — triggers protective antibodies and T-cells among older people, according to Reuters.